Organic Solvents Compromise Performance of Internal Standard (Ascomycin) in Proficiency Testing of Mass Spectrometry-Based Assays for Tacrolimus
To the Editor: Therapeutic drug monitoring of immunosuppressive agents by liquid chromatography (LC) coupled with mass spectrometry (MS) can provide highly selective and sensitive quantification from biological fluids. Interlaboratory performance for cyclosporine, tacrolimus, and sirolimus, as assessed by LC/MS, in proficiency testing (PT) programs [e.g., College of American Pathologists (CAP) (1 ) and the International Proficiency Testing Scheme (IPTS) (2 ) ] has been poor, albeit improving, although individual laboratories report excellent interassay imprecision (CV Ͻ5.5%) at drug concentrations across analytical ranges (3) (4) (5) (6) . Lack of industrywide standardization may contribute to variations in PT program performance across MS laboratories because it requires that those laboratories develop "home brew" assays, use reference materials with potentially different purities obtained from numerous sources, and prepare either whole-blood calibrator/qualitycontrol (QC) materials in house or purchase commercial materials that may be verified only for a specific procedure. In addition, most PT samples are unlike routine specimens, being prepared from either artificial or whole-blood-like matrices (sometimes pooled patient blood) that are subjected to the rigors of batch preparation and shipping.
I describe here an experience of specific and unusual performance of PT samples, which likely resulted from instabilities of the internal standard (IS) in organic solvents and which may be of value to scientists struggling with the development or long-term performance of MS-based methods and to PT program providers who wish to help marginally performing laboratories improve.
My laboratory has single-quadrupole LC/MS and tandem LC/ MS/MS systems with independent methods for tacrolimus. Both assays use ascomycin (Sigma-Aldrich) as IS and are based on protein precipitation with zinc sulfate and organic solvent. Tacrolimus (a kind gift of Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan) dissolved in acetonitrile (ACN) and stored at Ϫ40°C in glass is used for preparing wholeblood calibrators/QC materials. A common IS stock solution in ACN is stored at Ϫ40°C (ϳ1 mg in a 3-mL glass volumetric flask) and used to make the working IS for each assay.
The LC/MS IS working solution is prepared by diluting the stock to 10 mL in glass with ACN (2 ng/10 L) and storing at Ϫ20°C. Receipt of a "poor-quality" lot of ACN in which ascomycin in the LC/ MS/MS working solution degraded within hours required temporary abandonment of that assay because the extraction is dependent on a large volume of ACN. Thus, until substitute ACN could be found and evaluated, the LC/MS method was used with the LC/MS IS working solution prepared in methanol: sufficient original stock solution prepared in "good-quality" ACN was available to do this. As controlled by daily calibration curves, QC monitoring within and across runs, and the requirement for a CV Ͻ5% for withinrun IS peak height, the LC/MS assay performed as usual with a single preparation of IS working solution. A mean deviation from targeted concentrations of 1.2% (n ϭ 33) was observed in IPTS samples, whereas QC samples in IPTS-containing runs averaged 0.3% deviation (n ϭ 30). However, after 4 months, IPTS program performance began to deteriorate until it deviated from expected values by a mean of 27.1% by 7 months (see the table in the Data Supplement that accompanies the online version of this letter at http:// www.clinchem.org/content/vol52/ issue4/), whereas QC samples maintained an acceptable bias of 1.1%. In IPTS samples only, IS peak area decreased by ϳ50% and height by ϳ30%. Use of the tacrolimus peak alone yielded concentrations that were either at or below the targets (as expected with no correction by IS for extraction losses or ion suppression).
Fortunately, by this time 2 sources of ACN (Mallinckrodt UltimAR and EM science Omnisolv) in which ascomycin was stable over several months had been identified. The LC/ MS/MS IS working solution was therefore prepared by diluting the suspect methanolic LC/MS working solution with this new ACN. A series of IPTS samples analyzed with this solution showed a mean deviation of 10.5% (maximum, 21.1%; n ϭ 27) with QC samples at 3.4% (n ϭ 6), but all with normal IS peaks.
Preparation of the LC/MS IS working solution with the goodquality ACN corrected the problem, as evidenced by analysis of a series of 18 IPTS samples (deviation, 0.8%; deviation for QC samples, 3.2%; n ϭ 6). Similarly, an LC/MS/MS IS working solution prepared from this ACN-based LC/MS working solution gave a mean deviation of 1.3% for a series of IPTS samples (n ϭ 21; deviation for QC samples, 0.5%; n ϭ 12). Similar phenomena were observed with CAP samples (data not shown). Subsequent IPTS performance of both methods has been good: 3.7% deviation by LC/MS (n ϭ 30) with Ϫ1.0% deviation for QC samples, and Ϫ2.6% (n ϭ 36) by LC/MS/MS with Ϫ2.8% deviation for QC samples.
In To the Editor: B-Type natriuretic peptide (BNP) is a marker for diagnosis and prognosis of congestive heart failure (CHF). In response to the analytical uncertainties of automated BNP assays, the IFCC Committee on Standardization of Markers of Cardiac Damage published recommendations for the evaluation of in vitro BNP stability (1 ) .
We analyzed the effect of exposure to room temperature for 24 h on whole-blood BNP immunoreactivity or the effect of 1 freeze-thaw (FT) cycle on plasma BNP immunoreactivity in 3 different assays. Blood samples from 4 CHF patients were collected on ice with Sarstedt tubes containing potassium EDTA (1.6 mg/mL EDTA), EDTA with aprotinin (500 kallikrein-inhibitory units/ mL), and EDTA with benzamidine (80 mol/mL). Whole blood was split into 2 aliquots: one was centrifuged (2400g for 10 min) for immediate assay (baseline), with the remaining plasma stored at Ϫ20°C; the other aliquot was allowed to stand at room temperature for 24 h under constant gentle mixing before centrifugation and assay. The procedure generated a total of 36 aliquots. BNP recoveries were calculated as percentage of baseline.
Baseline BNP values were 1133-4854 ng/L (mean, 1789 ng/L) with the AxSYM (Abbott Diagnostics), 593-3232 ng/L (mean, 1106 ng/L) with the ADVIA Centaur (Bayer Diagnostics), and 540-3839 ng/L (mean, 1359 ng/L) with the Beckman Coulter Access 2 (BioSite reagents). These values were not affected by protease inhibitors (one-way ANOVA for effect of protease inhibitors, P ϭ 0.93, 0.92, and 0.95 for the AxSYM, Centaur, and Access 2, respectively). Exposure of whole blood to room temperature for 24 h led to a mean decrease of 21%. Neither the sampling conditions nor the assay affected BNP loss ( We also evaluated BNP stability during shorter storage times (room temperature and 4°C), without agitation, using conditions close to those likely to be used with samples from outpatient clinics or physicians' offices. EDTA samples from 5 CHF patients with baseline BNP values of 404-2746 ng/L (mean, 1623 ng/L) on the AxSYM, 232-1694 ng/L (mean, 933 ng/L) on the Centaur, and 234-1917 ng/L (mean, 985 ng/L) on the Access 2 were split and allowed to stand at room temperature and 4°C for 4 and 8 h before centrifugation and assay. At room temperature, mean (SD) measured values after 4 h were 88 (8)%, 94 (6)%, and 94 (6)% of the baseline values on the AxSYM, Centaur and Access 2, respectively, and after 8 h, the measured concentrations were 85 (14)%, 91 (7)%, and 89 (6)% of baseline values. At 4°C, after storage for 4 h, measured values were 95 (9)%, 90 (8)%, and 100 (17)% of baseline values on the AxSYM, Centaur, and Access 2, respectively, and after 8 h, they were 90 (10)%, 88 (10)%, and 99 (15)% of baseline values. No significant time or instrument effects were evidenced by ANOVA analysis for storage at room temperature (P ϭ 0.37 and 0.46, respectively) and 4°C (P ϭ 0.48 and 0.22, respectively). The overall loss of BNP reactivity was 10%, a value comparable to the effect of 1 FT cycle. At 4°C, loss of BNP immunoreactivity was somewhat lower, averaging 6%. Our results confirm the AxSYM claim, which was the only package insert (8G82-20) reporting the 4 h BNP stability at room temperature. In contrast, using the Biosite BNP POCT Triage ® meter, Yeo et al. (3 ) reported a significant BNP loss after 4 h of storage at room temperature.
In conclusion, our data indicate that protease inhibition does not pro-
